American Society of Clinical Oncology (ASCO) 2016 Coverage

Older patients with chronic myeloid leukemia (CML) may have higher mortality and rates of vascular e

ASCO 2016

Older Pts With NSCLC Receiving CRT Had Worse OS, Similar PFS vs Younger Pts

By

June 4, 2016

Older patients receiving concurrent chemoradiotherapy for stage III non-small cell lung cancer (NSCLC) had worse overall survival.

Type of chemotherapy regimen for the treatment of patients with stage 3 non-small cell lung cancer (

ASCO 2016

Geriatric Assessment May Improve Selection of Older Patients for Concurrent CRT

By

Jason Hoffman, PharmD, RPh

June 4, 2016

Geriatric assessmentmay improve the selection of older patients with stage III non-small cell lung cancer (NSCLC).

KRAS is commonly mutated in non-small cell lung cancer (NSCLC), but targeting KRAS directly has been

ASCO 2016

Nivolumab ± Ipilimumab Induces Durable Responses in Previously Treated SCLC

By

Jason Hoffman, PharmD, RPh

June 4, 2016

Nivolumab with or without ipilimumab was associated with manageable safety profiles in previously treated advanced small cell lung cancer (SCLC).

Vice President Joe Biden said that improved data sharing, recruiting more patients into clinical tri

ASCO 2016

Researchers Identify Patients With Ultra High-risk Smoldering Myeloma

By

Jason Hoffman, PharmD, RPh

June 3, 2016

Patients with smoldering myeloma with evolving change in monoclonal protein (eMP) ahad higher risk of progression to multiple myeloma.

Increased oversight, common evidentiary standards, and a structured system for collecting patient da

ASCO 2016

Molecular Profiles Differ Between High-risk Smoldering Myeloma, Newly Diagnosed Multiple Myeloma

By

Jason Hoffman, PharmD, RPh

June 3, 2016

A proportion of patients, at least, with high-risk smoldering myeloma have different molecular profiles compared with patients with newly diagnosed multiple myeloma.

In thyroid cancer with and without prior exposure to VEGF therapy, the response rates and survival f

ASCO 2016

Cediranib Alone Linked to Higher PFS Than in Conjunction With Lenalidomide for Differentiated Thyroid Cancer (DTC)

By

Jonathan Goodman, MPhil

June 2, 2016

Cediranib in conjunction with lenalidomide is evidently not a more effective therapy for patients with advanced differentiated thyroid cancer (DTC).

ASCO 2016

Older Pts With NSCLC Receiving CRT Had Worse OS, Similar PFS vs Younger Pts

Geriatric Assessment May Improve Selection of Older Patients for Concurrent CRT

Nivolumab ± Ipilimumab Induces Durable Responses in Previously Treated SCLC

Researchers Identify Patients With Ultra High-risk Smoldering Myeloma

Molecular Profiles Differ Between High-risk Smoldering Myeloma, Newly Diagnosed Multiple Myeloma

Cediranib Alone Linked to Higher PFS Than in Conjunction With Lenalidomide for Differentiated Thyroid Cancer (DTC)

Want to read more?

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma